Tags

Type your tag names separated by a space and hit enter

Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
J Gen Virol. 2015 Apr; 96(Pt 4):804-814.JG

Abstract

Yellow fever virus (YFV)-17D is an empirically developed, highly effective live-attenuated vaccine that has been administered to human beings for almost a century. YFV-17D has stood as a paradigm for a successful viral vaccine, and has been exploited as a potential virus vector for the development of recombinant vaccines against other diseases. In this study, a DNA-launched YFV-17D construct (pBeloBAC-FLYF) was explored as a new modality to the standard vaccine to combine the commendable features of both DNA vaccine and live-attenuated viral vaccine. The DNA-launched YFV-17D construct was characterized extensively both in cell culture and in mice. High titres of YFV-17D were generated upon transfection of the DNA into cells, whereas a mutant with deletion in the capsid-coding region (pBeloBAC-YF/ΔC) was restricted to a single round of infection, with no release of progeny virus. Homologous prime-boost immunization of AAD mice with both pBeloBAC-FLYF and pBeloBAC-YF/ΔC elicited specific dose-dependent cellular immune response against YFV-17D. Vaccination of A129 mice with pBeloBAC-FLYF resulted in the induction of YFV-specific neutralizing antibodies in all vaccinated subjects. These promising results underlined the potential of the DNA-launched YFV both as an alternative to standard YFV-17D vaccination and as a vaccine platform for the development of DNA-based recombinant YFV vaccines.

Authors+Show Affiliations

Department of Medical Microbiology, Center of Infectious Diseases, Leiden University Medical Center, P. O. Box 9600, 2300 RC Leiden, The Netherlands.Department of Medical Microbiology, Center of Infectious Diseases, Leiden University Medical Center, P. O. Box 9600, 2300 RC Leiden, The Netherlands.Department of Pharmacology and Toxicology, School of Medicine, Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, NIH Regional Bio-containment Laboratory, University of Louisville, KY, USA.Department of Medical Microbiology, Center of Infectious Diseases, Leiden University Medical Center, P. O. Box 9600, 2300 RC Leiden, The Netherlands.Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, New York, NY 10016, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25516543

Citation

Jiang, Xiaohong, et al. "Molecular and Immunological Characterization of a DNA-launched Yellow Fever Virus 17D Infectious Clone." The Journal of General Virology, vol. 96, no. Pt 4, 2015, pp. 804-814.
Jiang X, Dalebout TJ, Lukashevich IS, et al. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone. J Gen Virol. 2015;96(Pt 4):804-814.
Jiang, X., Dalebout, T. J., Lukashevich, I. S., Bredenbeek, P. J., & Franco, D. (2015). Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone. The Journal of General Virology, 96(Pt 4), 804-814. https://doi.org/10.1099/jgv.0.000026
Jiang X, et al. Molecular and Immunological Characterization of a DNA-launched Yellow Fever Virus 17D Infectious Clone. J Gen Virol. 2015;96(Pt 4):804-814. PubMed PMID: 25516543.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone. AU - Jiang,Xiaohong, AU - Dalebout,Tim J, AU - Lukashevich,Igor S, AU - Bredenbeek,Peter J, AU - Franco,David, Y1 - 2014/12/16/ PY - 2014/12/18/entrez PY - 2014/12/18/pubmed PY - 2015/5/23/medline SP - 804 EP - 814 JF - The Journal of general virology JO - J Gen Virol VL - 96 IS - Pt 4 N2 - Yellow fever virus (YFV)-17D is an empirically developed, highly effective live-attenuated vaccine that has been administered to human beings for almost a century. YFV-17D has stood as a paradigm for a successful viral vaccine, and has been exploited as a potential virus vector for the development of recombinant vaccines against other diseases. In this study, a DNA-launched YFV-17D construct (pBeloBAC-FLYF) was explored as a new modality to the standard vaccine to combine the commendable features of both DNA vaccine and live-attenuated viral vaccine. The DNA-launched YFV-17D construct was characterized extensively both in cell culture and in mice. High titres of YFV-17D were generated upon transfection of the DNA into cells, whereas a mutant with deletion in the capsid-coding region (pBeloBAC-YF/ΔC) was restricted to a single round of infection, with no release of progeny virus. Homologous prime-boost immunization of AAD mice with both pBeloBAC-FLYF and pBeloBAC-YF/ΔC elicited specific dose-dependent cellular immune response against YFV-17D. Vaccination of A129 mice with pBeloBAC-FLYF resulted in the induction of YFV-specific neutralizing antibodies in all vaccinated subjects. These promising results underlined the potential of the DNA-launched YFV both as an alternative to standard YFV-17D vaccination and as a vaccine platform for the development of DNA-based recombinant YFV vaccines. SN - 1465-2099 UR - https://www.unboundmedicine.com/medline/citation/25516543/Molecular_and_immunological_characterization_of_a_DNA_launched_yellow_fever_virus_17D_infectious_clone_ L2 - http://jgv.microbiologyresearch.org/pubmed/content/journal/jgv/10.1099/jgv.0.000026 DB - PRIME DP - Unbound Medicine ER -